Cancer Immunology Conference 2027

For immunology tool vendors

A cancer immunology conference where the buyers run the experiments

ImmunoMark is a cancer immunology conference for the industry side of the field: two days in which translational immunologists from biotech and pharma discuss the T cell, NK cell, myeloid and tumour microenvironment biology that decides whether an immunotherapy works.

If you sell antibodies and reagents, cytometry instruments and panels, immune-profiling services, multiplex assays or spatial tools for TME characterisation, those discussions are your product’s use cases. The people giving and hearing them specify what goes into the next study, and many of them hold the budget for it.

On the crowded calendar of immunotherapy conferences, the useful filter for a tool vendor is simple: how many of the people in the room both understand your application data and can act on it? ImmunoMark’s published audience mix answers that directly.

55–60%of delegates from biotech and pharma

20–30%scientists, PIs and technologists

45–50%senior leadership: executives, directors, heads

10–15%academic and research roles

Tool category map

What translational immunologists are working on, by tool category

Each row links a tool category to real sessions on the published 2027 agendas, so you can see where your applications will come up in conversation.

Your tool category	Where it comes up on the agenda	The conversation to have
Flow and spectral cytometry, immune-monitoring panels	Functional T cell Biomarkers for Precision Immuno-Oncology (London, Stream 2); Single-Cell Technologies and Functional Biomarkers Driving the Future of Precision Oncology (San Diego, Stream 2)	Panel design and standardisation for functional T cell readouts in trials
Antibodies and reagents for myeloid biology	Therapeutic Targeting of Human LILRBs: A Novel Class of Myeloid Checkpoint Inhibitors (London, Stream 1)	Validated clones and assays for emerging myeloid targets
TME characterisation: spatial, multiplex imaging, digital pathology	Reprogramming the Tumour Microenvironment to Overcome Resistance to Cancer Immunotherapy (San Diego, Stream 1); Digital Pathology & Spatial Transcriptomics in Oncology (London, Stream 2)	Mapping immune infiltrates before and after treatment
Cell therapy phenotyping and potency	Emerging NK Cell, TIL and In Vivo CAR Platforms Reshaping Cancer Immunotherapy (San Diego, Stream 1)	Persistence, exhaustion and potency assays for engineered cells
Antigen discovery and T cell assays	Personalised Cancer Vaccines and Neoantigen Discovery for Next-Generation Immunotherapies (San Diego, Stream 1)	Epitope screening and antigen-specific T cell detection
Bioassays for engagers	Bispecific and Multispecific Immune Engagers (London, Stream 1)	Cytotoxicity, cytokine release and target-engagement assays
Microbiome and host-response profiling	Harnessing the Human Microbiome to Enhance Immunotherapy Response and Patient Outcomes (San Diego, Stream 1)	Linking microbiome signatures to immune response data

Note how often the immunology sits in Stream 2 as well as Stream 1. If your product is mainly a multiplex or spatial platform, the biomarker technology page covers that angle, and our explainer on spatial proteomics vs spatial transcriptomics is useful context for TME conversations.

The buyer

The tumour immunology conference buyer: who specifies, who signs

Tool sales in immunology usually need two people: the scientist who chooses the method and the leader who approves the spend. Both are in the delegate list.

The scientist who specifies

Principal scientists, group leaders and senior investigators
Departments listed include Immunology / Tumor Immunology and Cancer Biology
Wants application data, panel designs and a technical contact
Best reached through your talk and the booth

The leader who signs

Heads and directors of translational medicine, biomarker operations leads
VP translational strategy and VP oncology R&D profiles
Wants turnaround, data quality and a partner who scales
Best reached through pre-scheduled 1:1 meetings

Whether your US team would call this a tumor immunology conference or your European team a cancer immunotherapy conference, the buyer profile is the same. Tool companies already use it: LUMICKS, PromoCell, CellCarta, Seer, HAWK Biosystems and Hologic Diagenode all had people on the London 2026 speaker panel.

Series view

Choosing an edition for an immunology tools business

The packages are identical at every edition. What changes is where your field applications scientists and distributors are based.

San Diego, 10–11 February 2027

Launch edition, 300+ senior attendees expected. Stream 1 is strong on engineered cells, neoantigen vaccines and the tumour microenvironment, all assay-heavy areas. See the San Diego Stream 1 page.

London, 3–4 March 2027

2nd annual, 400+ target, delegates 60% UK and Ireland and 40% rest of Europe. Myeloid checkpoints, allogeneic cells and engagers feature in Stream 1. See the London Stream 1 page.

Boston, June 2027

Launch edition, 300+ attendees expected. The agenda is still to be published, so it suits vendors who want a mid-year US date once the first two editions are done.

For an edition-by-edition comparison written for therapy-side IO vendors, see the immuno-oncology summit page.

Packages

Which package fits an immunology reagent or profiling vendor

Tool vendors need three things: a booth to demonstrate, a stage for application data and meetings with the people who sign. Gold covers all three.

Best fit

Gold, Stream 1

A 30-minute Day 2 talk before lunch is the right length for an application case study, and the booth keeps your demos running for both days.

30-minute Day 2 talk plus Q&A
6 pre-scheduled 1:1 meetings
6 team + 6 client passes, 10 x 6 ft booth
Attendee list a week before, half-page brochure advertisement

Exhibitor

For a focused reagent or antibody portfolio where the demo does the selling.

10 x 6 ft booth with table, chairs and power
2 team + 2 client passes
Wishlist and delegate list with contacts
Website and brochure logo

Exclusive 1:1 Meetings

For immune-profiling service labs that sell to translational leads in private.

3, 5, 7 or 10 meetings of 20 minutes
2–4 passes plus drinks reception passes
Profiles to choose from 10 days before

Tier details for each edition: San Diego sponsorship opportunities and London sponsorship opportunities.

Tell us your tool category and we will point you to the sessions and package that fit.

Request the prospectus

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Is ImmunoMark a scientific cancer immunology meeting or an industry event?

It is industry-led. 55–60% of delegates come from biotech and pharma and 10–15% from academia, with 45–50% in senior leadership and 20–30% scientists, PIs and technologists. The sessions are scientific, but most of the people in them are in a position to buy.

Can a reagent or antibody company give a technical talk?

Yes. Gold sponsors get a 30-minute talk on Day 2 before lunch and Silver sponsors a 15-minute talk on Day 2 after lunch, each in the stream they choose. Platinum sponsors get a 30-minute talk on Day 1.

How do we reach both bench scientists and budget holders?

Use the talk and the booth for scientists who specify methods, and pre-scheduled 1:1 meetings for translational and biomarker leads who approve spend. You choose meetings from the full delegate list and profiles sent 10 days before the event, and the wishlist feature helps target the rest.

Should an immunology tools vendor choose Stream 1 or Stream 2?

Choose Stream 1, Next-Gen Immuno-Oncology, if your applications are in cell therapy, myeloid biology, engagers or the tumour microenvironment. Choose Stream 2, Biomarkers & Companion Diagnostics, if your story is about functional biomarkers, single-cell or spatial readouts used in trials.

Which edition suits a European versus a US tools business?

London (3–4 March 2027) draws 60% of delegates from the UK and Ireland and 40% from the rest of Europe. San Diego (10–11 February 2027) and Boston (June 2027) are the US launch editions. The packages are the same at all three.

Cancer Immunology Conference Sponsorship for Immunology Tool Vendors

Get the prospectus and package availability